Market Overview

UPDATE: Bank of America Raises PO to $173 on Biogen Idec on Strong Hemophilia Data

Share:
Related BIIB
Biogen Optionality Looking Attractive; Bernstein Initiates At Outperform
Stiff Biosimilar Headwinds To Negatively Impact Amgen's Aging Drug Portfolio
Is The Bottom In For Biotech? (Seeking Alpha)

Bank of America reiterated its Buy rating on Biogen Idec (NASDAQ: BIIB) and raised its price objective from $157 to $173.

Bank of America said, "BIIB and partner SOBI reported positive and better-than-expected Phase 3 results for their first long-acting hemophilia program, rFIXFc. This program targets a smaller portion of the $6B global hemophilia market ($1B), but gives us increased confidence overall in the long-acting technology that supports the $5B global Factor 8 market. Based on these results, we are increasing our PO from $157 to $173, driven by higher probability of success for the entire hemophilia program, higher sales estimates for rFIXFc, and adjusting our model for better economics to BIIB."

Biogen Idec closed at $152.83 on Tuesday.

Latest Ratings for BIIB

DateFirmActionFromTo
Jun 2016BernsteinInitiates Coverage onOutperform
Jun 2016CitigroupMaintainsBuy
Jun 2016CitigroupDowngradesBuyNeutral

View More Analyst Ratings for BIIB
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (BIIB)

View Comments and Join the Discussion!